TFMPP is rarely used by itself. In fact, TFMPP reduces locomotor activity and produces aversive effects in animals rather than self-administration, which may explain the decision of the DEA not to permanently make TFMPP a controlled substance.[5] More commonly, TFMPP is co-administered with BZP, which acts as a norepinephrine and dopamine releasing agent.[6] Due to the serotonin agonist effects and increase in serotonin, norepinephrine, and dopamine levels produced by the BZP/TFMPP combination, this mixture of drugs produces effects which crudely mimic those of MDMA.[7]
In clinical studies, TFMPP produced effects in humans including dysphoria, dextroamphetamine-like effects (i.e., stimulant-like effects), tension and anxiety, mental confusion and “bewilderment”, and increased ratings of “drug liking“, “high”, and “stimulated”.[8][9] The drug has been anecdotally reported to produce mild psychedelic effects in humans, but no hallucinogenic effects with the drug were described in clinical studies at the employed dose.[8][9] The combination of TFMPP with BZP crudely mimics the effects of MDMA in clinical studies.[9][10]
However, it is difficult to say how many of these side effects are produced by TFMPP itself, as it has rarely been marketed without BZP also being present, and all of the side effects mentioned are also produced by BZP (which has been sold as a single drug). Studies into other related piperazine drugs such as mCPP suggest that certain side effects such as anxiety, headache and nausea are common to all drugs of this class, and pills containing TFMPP are reported by users to produce comparatively more severe hangover effects than those containing only BZP. The drug can also cause the body to tremble for a long period of time.[11][unreliable source?]
Findings are mixed on whether TFMPP produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, with some studies finding that it does and others reporting that it does not.[15][16][17][18] In one study, TFMPP did not produce the head-twitch response on its own, but when combined with the selective serotonin 5-HT2C receptor antagonist SB-242084, it was able to dose-dependently induce head twitches.[16] In contrast to the preceding findings, the drug has been found to dose-dependently antagonize the head-twitch response induced by serotonergic psychedelics like DOI.[16][17][19][18] The preceding findings suggest that serotonin 5-HT2C receptor activation inhibits and can mask the head-twitch response induced by serotonin 5-HT2A receptor agonists.[16]
Since 2012, TFMPP has been listed as a Schedule III controlled substance in Canada,[26] making possession of TFMPP a federal offence. It has also been added to Part J of the Food and Drug Regulations thereby prohibiting the production, export or import of the substance.
China
As of October 2015 TFMPP is a controlled substance in China.[27]
Denmark
As of December 3, 2005, TFMPP is illegal in Denmark.
Finland
Scheduled in government decree on psychoactive substances banned from the consumer market.[28][29][30]
Japan
Since 2003, TFMPP and BZP became illegal in Japan.
Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with the other piperazine derivatives TFMPP, mCPP, pFPP, MeOPP and MBZP, into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18, 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1 April 2008. An amnesty for possession and usage of these drugs remained until October 2008, at which point they became completely illegal.[32]
Sweden
As of March 1, 2006, TFMPP is scheduled as a “dangerous substance” in Sweden.[33]
Switzerland
As of December 1, 2010, TFMPP is a controlled substance in Switzerland.[34][35]
United Kingdom
As of December 2009, TFMPP has been made a Class C drug in the United Kingdom along with BZP.
United States
TFMPP is not currently scheduled at the federal level in the United States,[36] but it was briefly emergency scheduled in Schedule I. The scheduling expired in April 2004 and was not renewed.[37] However, some states such as Florida have banned the drug in their criminal statutes making its possession a felony.[38]
Florida
TFMPP is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[38]
Texas
TFMPP is controlled in Texas under Penalty Group 2, as a hallucinogenic substance. It is illegal to possess TFMPP in any quantity in Texas.
^Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (October 2006). “Interaction of amphetamines and related compounds at the vesicular monoamine transporter”. The Journal of Pharmacology and Experimental Therapeutics. 319 (1): 237–246. CiteSeerX10.1.1.690.6669. doi:10.1124/jpet.106.103622. PMID16835371. S2CID22730478.
^ abJan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, et al. (August 2010). “Determining the subjective effects of TFMPP in human males”. Psychopharmacology. 211 (3): 347–353. doi:10.1007/s00213-010-1911-y. PMID20552171.
^ abcLin JC, Jan RK, Kydd RR, Russell BR (September 2011). “Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination”. Drug Testing and Analysis. 3 (9): 582–585. doi:10.1002/dta.285. PMID21538945.
^Lin JC, Jan RK, Lee H, Jensen MA, Kydd RR, Russell BR (April 2011). “Determining the subjective and physiological effects of BZP combined with TFMPP in human males”. Psychopharmacology. 214 (3): 761–768. doi:10.1007/s00213-010-2081-7. PMID21060995.
^Glennon RA (January 1987). “Central serotonin receptors as targets for drug research”. Journal of Medicinal Chemistry. 30 (1): 1–12. doi:10.1021/jm00384a001. PMID3543362. Table II. Affinities of Selected Phenalkylamines for 5-HT1 and 5-HT2 Binding Sites
^Robertson DW, Bloomquist W, Wong DT, Cohen ML (1992). “mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors”. Life Sciences. 50 (8): 599–605. doi:10.1016/0024-3205(92)90372-V. PMID1736030.
^ abcdVickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, et al. (2001). “Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists”. Pharmacology, Biochemistry, and Behavior. 69 (3–4): 643–652. doi:10.1016/s0091-3057(01)00552-4. PMID11509227.
^ abSchreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (April 1995). “(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists”. The Journal of Pharmacology and Experimental Therapeutics. 273 (1): 101–112. doi:10.1016/S0022-3565(25)09485-6. PMID7714755.
^ abSimansky KJ, Schechter LE (December 1988). “Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents”. The Journal of Pharmacology and Experimental Therapeutics. 247 (3): 1073–1081. doi:10.1016/S0022-3565(25)13260-6. PMID3144595.
^Olivier B, Mos J, van Oorschot R, Hen R (October 1995). “Serotonin receptors and animal models of aggressive behavior”. Pharmacopsychiatry. 28 Suppl 2: 80–90. doi:10.1055/s-2007-979624. PMID8614705.
^Muehlenkamp F, Lucion A, Vogel WH (April 1995). “Effects of selective serotonergic agonists on aggressive behavior in rats”. Pharmacology, Biochemistry, and Behavior. 50 (4): 671–674. doi:10.1016/0091-3057(95)00351-7. PMID7617717.
^Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A (February 2005). “Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys”. Drug and Alcohol Dependence. 77 (2): 161–168. doi:10.1016/j.drugalcdep.2004.07.014. PMID15664717.
^Antia U, Tingle MD, Russell BR (September 2010). “Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans”. Journal of Forensic Sciences. 55 (5): 1311–1318. doi:10.1111/j.1556-4029.2010.01457.x. PMID20533987.
^Fuller RW, Snoddy HD, Mason NR, Molloy BR (November 1978). “Effect of 1-(m-trifluoromethylphenyl)-piperazine on 3H-serotonin binding to membranes from rat brain in vitro and on serotonin turnover in rat brain in vivo”. European Journal of Pharmacology. 52 (1): 11–16. doi:10.1016/0014-2999(78)90016-x. PMID720384.